Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 135

1.

Large-scale molecular comparison of human schwann cells to malignant peripheral nerve sheath tumor cell lines and tissues.

Miller SJ, Rangwala F, Williams J, Ackerman P, Kong S, Jegga AG, Kaiser S, Aronow BJ, Frahm S, Kluwe L, Mautner V, Upadhyaya M, Muir D, Wallace M, Hagen J, Quelle DE, Watson MA, Perry A, Gutmann DH, Ratner N.

Cancer Res. 2006 Mar 1;66(5):2584-91.

2.

Genome-wide transcriptome analyses reveal p53 inactivation mediated loss of miR-34a expression in malignant peripheral nerve sheath tumours.

Subramanian S, Thayanithy V, West RB, Lee CH, Beck AH, Zhu S, Downs-Kelly E, Montgomery K, Goldblum JR, Hogendoorn PC, Corless CL, Oliveira AM, Dry SM, Nielsen TO, Rubin BP, Fletcher JA, Fletcher CD, van de Rijn M.

J Pathol. 2010 Jan;220(1):58-70. doi: 10.1002/path.2633.

3.

Molecular-guided therapy predictions reveal drug resistance phenotypes and treatment alternatives in malignant peripheral nerve sheath tumors.

Peacock JD, Cherba D, Kampfschulte K, Smith MK, Monks NR, Webb CP, Steensma M.

J Transl Med. 2013 Sep 17;11:213. doi: 10.1186/1479-5876-11-213.

4.

Brain lipid binding protein in axon-Schwann cell interactions and peripheral nerve tumorigenesis.

Miller SJ, Li H, Rizvi TA, Huang Y, Johansson G, Bowersock J, Sidani A, Vitullo J, Vogel K, Parysek LM, DeClue JE, Ratner N.

Mol Cell Biol. 2003 Mar;23(6):2213-24.

5.

Survivin is a viable target for the treatment of malignant peripheral nerve sheath tumors.

Ghadimi MP, Young ED, Belousov R, Zhang Y, Lopez G, Lusby K, Kivlin C, Demicco EG, Creighton CJ, Lazar AJ, Pollock RE, Lev D.

Clin Cancer Res. 2012 May 1;18(9):2545-57. doi: 10.1158/1078-0432.CCR-11-2592. Epub 2012 Mar 8.

6.

NF1 deficiency causes Bcl-xL upregulation in Schwann cells derived from neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors.

Park HJ, Lee SJ, Sohn YB, Jin HS, Han JH, Kim YB, Yim H, Jeong SY.

Int J Oncol. 2013 Feb;42(2):657-66. doi: 10.3892/ijo.2012.1751. Epub 2012 Dec 24.

PMID:
23292448
7.
8.

MicroRNA-21 correlates with tumorigenesis in malignant peripheral nerve sheath tumor (MPNST) via programmed cell death protein 4 (PDCD4).

Itani S, Kunisada T, Morimoto Y, Yoshida A, Sasaki T, Ito S, Ouchida M, Sugihara S, Shimizu K, Ozaki T.

J Cancer Res Clin Oncol. 2012 Sep;138(9):1501-9. doi: 10.1007/s00432-012-1223-1. Epub 2012 Apr 22.

PMID:
22526161
9.

An ShRNA Screen Identifies MEIS1 as a Driver of Malignant Peripheral Nerve Sheath Tumors.

Patel AV, Chaney KE, Choi K, Largaespada DA, Kumar AR, Ratner N.

EBioMedicine. 2016 Jul;9:110-9. doi: 10.1016/j.ebiom.2016.06.007. Epub 2016 Jun 4.

10.
11.

Inhibition of Eyes Absent Homolog 4 expression induces malignant peripheral nerve sheath tumor necrosis.

Miller SJ, Lan ZD, Hardiman A, Wu J, Kordich JJ, Patmore DM, Hegde RS, Cripe TP, Cancelas JA, Collins MH, Ratner N.

Oncogene. 2010 Jan 21;29(3):368-79. doi: 10.1038/onc.2009.360. Epub 2009 Nov 9.

12.

Microarray-based copy number analysis of neurofibromatosis type-1 (NF1)-associated malignant peripheral nerve sheath tumors reveals a role for Rho-GTPase pathway genes in NF1 tumorigenesis.

Upadhyaya M, Spurlock G, Thomas L, Thomas NS, Richards M, Mautner VF, Cooper DN, Guha A, Yan J.

Hum Mutat. 2012 Apr;33(4):763-76. doi: 10.1002/humu.22044. Epub 2012 Mar 5.

PMID:
22331697
13.

Ras-driven transcriptome analysis identifies aurora kinase A as a potential malignant peripheral nerve sheath tumor therapeutic target.

Patel AV, Eaves D, Jessen WJ, Rizvi TA, Ecsedy JA, Qian MG, Aronow BJ, Perentesis JP, Serra E, Cripe TP, Miller SJ, Ratner N.

Clin Cancer Res. 2012 Sep 15;18(18):5020-30. doi: 10.1158/1078-0432.CCR-12-1072. Epub 2012 Jul 18.

14.

Transgenic mice overexpressing neuregulin-1 model neurofibroma-malignant peripheral nerve sheath tumor progression and implicate specific chromosomal copy number variations in tumorigenesis.

Kazmi SJ, Byer SJ, Eckert JM, Turk AN, Huijbregts RP, Brossier NM, Grizzle WE, Mikhail FM, Roth KA, Carroll SL.

Am J Pathol. 2013 Mar;182(3):646-67. doi: 10.1016/j.ajpath.2012.11.017. Epub 2013 Jan 13.

15.

Neuregulin-1 beta and neuregulin-1 alpha differentially affect the migration and invasion of malignant peripheral nerve sheath tumor cells.

Eckert JM, Byer SJ, Clodfelder-Miller BJ, Carroll SL.

Glia. 2009 Nov 1;57(14):1501-20. doi: 10.1002/glia.20866.

16.

Chemically induced rat Schwann cell neoplasia as a model for early-stage human peripheral nerve sheath tumors: phenotypic characteristics and dysregulated gene expression.

Koelsch B, van den Berg L, Grabellus F, Fischer C, Kutritz A, Kindler-Röhrborn A.

J Neuropathol Exp Neurol. 2013 May;72(5):404-15. doi: 10.1097/NEN.0b013e31828ea4ac.

PMID:
23584200
17.

Malignant peripheral nerve sheath tumors with high and low Ras-GTP are permissive for oncolytic herpes simplex virus mutants.

Mahller YY, Rangwala F, Ratner N, Cripe TP.

Pediatr Blood Cancer. 2006 Jun;46(7):745-54.

PMID:
16124003
18.
19.

Genomic amplification and high expression of EGFR are key targetable oncogenic events in malignant peripheral nerve sheath tumor.

Du X, Yang J, Ylipää A, Zhu Z.

J Hematol Oncol. 2013 Dec 17;6:93. doi: 10.1186/1756-8722-6-93.

20.

Supplemental Content

Support Center